Currently

molecularly target therapy has increasingly altered the strategies in advanced non-small cell lung cancer (NSCLC). Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)

gefitinib and erlotinib

are regarded as the most successful target drugs. However

EGFR-TKIs resistance has become a major clinical challenge. EGFR-TKIs resistance includes the primary resistance and the acquired resistance. The primary resistance’s mechanisms are associated with other non-sensitive EGFR mutations such as exon 20 insertions and other gene mutations such as KRAS

BRAF and EML4-ALK. The acquired resistance’s mechanisms are often associated with the secondary T790 mutation and MET gene amplification. At present

new strategies in overcoming EGFR-TKIs resistance are mainly focusing on irreversible EGFR inhibitors and MET inhibitors.